Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Industrial-Scale Production of Human Pluripotent Stem Cells Using Novel Media and Bioreactors

Reference number
Coordinator Lancell AB
Funding from Vinnova SEK 1 000 000
Project duration November 2024 - October 2025
Status Ongoing
Venture Utlysning Infrastruktur for the development of accurate drug treatment
Call Use infrastructures to develop precision medicine

Purpose and goal

The aim is to test Lancell AB´s patented human pluripotent stem cel media in new innovative bioreactors that have not previously been used for human pluripotent stem cell production. The goal is to create a solution for stem cell culture that is significantly more effective and cost-effective than existing options.

Expected effects and result

The expected results are a new type of solution for stem cell production on an industrial scale that is significantly more efficient and cost-effective than existing solutions.

Planned approach and implementation

The planned setup is for the stem cell medium to be tested in a new type of bioreactor with human pluripotent stem cells, and where several technical aspects are to be optimized to develop a protocol that can be used for industrial use. The quality of the cells will be checked according to industry standards.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 12 November 2024

Reference number 2024-02551